10x Genomics, Inc. (TXG) Stock Overview
Explore 10x Genomics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
10x Genomics, Inc. (TXG)
Key Financials
Key Financials
Market Cap
11.4B
P/E Ratio
-153.52
EPS (TTM)
$-0.59
ROE
-0.09%
TXG Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of 10x Genomics, Inc. (NASDAQ: TXG) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, 10x Genomics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TXG on the NASDAQ shows an RSI of 77.02, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $37.55 for the NASDAQ listing.
Key metrics behind 10x Genomics, Inc.'s NASDAQ-traded stock include a P/E ratio of -153.52 and a market capitalization of 11.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TXG on the NASDAQ.